- Home
- TRC vs STTK Comparison
TRC vs STTK Comparison
Compare TRC & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRC | STTK |
|---|---|---|
| Founded | 1843 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.8M | 569.1M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRC | STTK |
|---|---|---|
| Price | $20.37 | $7.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 73.9K | ★ 421.2K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,830,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.31 | $0.71 |
| 52 Week High | $20.68 | $8.33 |
Technical Indicators
Market Signals| Indicator | TRC | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 66.24 | 59.44 |
| Support Level | $19.24 | $1.85 |
| Resistance Level | N/A | $7.68 |
| Average True Range (ATR) | 0.37 | 0.47 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 64.19 | 42.42 |
Price Performance
Historical ComparisonAbout TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company. It has six reporting segments: Real Estate - Commercial/Industrial, Multifamily, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.